Soleno Therapeutics, Inc. (SLNO)
May 18, 2026 - SLNO was delisted (reason: acquired by NBIX)
53.01
0.00 (0.00%)
Inactive · Last trade price
on May 15, 2026
Soleno Therapeutics Employees
Soleno Therapeutics had 182 employees as of December 31, 2025. The number of employees increased by 90 or 97.83% compared to the previous year.
Employees
182
Change (1Y)
90
Growth (1Y)
97.83%
Revenue / Employee
$1,565,978
Profits / Employee
$525,418
Market Cap
2.76B
Employees Chart
SLNO News
- 2 months ago - Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers - GlobeNewsWire
- 2 months ago - Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders? - PRNewsWire
- 2 months ago - SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline - GlobeNewsWire
- 2 months ago - Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - Reuters
- 2 months ago - Neurocrine to Buy Soleno for $2.9 Billion - WSJ
- 2 months ago - Neurocrine to buy Soleno Therapeutics for $2.9 billion - Reuters
- 2 months ago - Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PRNewsWire
- 3 months ago - SLNO Stockholders Have Rights – If You Lost Money Investing in Soleno Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses - GlobeNewsWire